At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 10 enrolled

Drug / intervention

25% Mannitol +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02819479

NCT02819479Phase 2Completed

Compare CT.gov

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Norton Healthcare·interventional·Posted Jun 30, 2016·Updated May 24, 2022

In Brief

A Phase 2 clinical trial evaluating 25% Mannitol and Low-dose Intra-arterial Bevacizumab for Radiation Necrosis. Completed, enrolled 10 participants across 2 sites.

Detailed Summary

To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given intra-arterially after osmotic blood-brain-barrier disruption.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsRadiation Necrosis

CountriesUnited States

CollaboratorsUniversity of Kentucky

Timeline

Phase 2CompletedFinished

2017201820192020202120222023202420252026

First PostedJun 2016

Enrollment StartNov 2016

Primary CompletionJun 2019

TodayJul 2026

First PostedJun 30, 2016

Enrollment StartNov 23, 2016

Primary CompletionJun 6, 2019

TodayJul 2, 2026

Enrollment to primary: 2.5 yearsPosted 10.0 years ago

Interventions

25% Mannitoldrug

Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.

Low-dose Intra-arterial Bevacizumabdrug

Route of administration: In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery.